RESUMEN
TITLE: Déficit de ADA2: caso con manifestaciones neurológicas como clínica predominante.
Asunto(s)
Adenosina Desaminasa/deficiencia , Isquemia Encefálica/genética , Péptidos y Proteínas de Señalización Intercelular/deficiencia , Adenosina Desaminasa/genética , Isquemia Encefálica/diagnóstico por imagen , Etanercept/uso terapéutico , Femenino , Ataxia de la Marcha/genética , Pérdida Auditiva Central/genética , Homocigoto , Humanos , Lactante , Péptidos y Proteínas de Señalización Intercelular/genética , Imagen por Resonancia Magnética , Mutación Missense , Neuroimagen , Enfermedades del Nervio Oculomotor/genética , Paresia/genética , Mutación PuntualRESUMEN
Pott's puffy tumor is a rare complication of frontal sinusitis characterized by swelling and edema in the brow due to a subperiosteal abscess associated with frontal osteomyelitis. Added complications are cellulitis by extension to the orbit and intracranial infection by posterior extension, with high risk of meningitis, intracranial abscess, and venous sinus thrombosis. Early diagnosis and aggressive medical or surgical treatment are essential for optimal recovery of affected patients. In the antibiotic age it is extremely rare, with very few cases described in the recent literature. A case is presented of a Pott inflammatory tumor in a 7 year-old boy, as a complication of acute pansinusitis who presented with front preseptal swelling and intracranial involvement with thrombosis of ophthalmic and superior orbital veins and frontal epidural abscess extending to the subarachnoid space.
Asunto(s)
Sinusitis Frontal/complicaciones , Tumor Hinchado de Pott/etiología , Niño , Humanos , MasculinoRESUMEN
OBJECTIVES: To evaluate the response to calcitonin treatment in critically ill children with hypercalcemia due to immobilization. PATIENTS AND METHODS: Four children aged 3-14 years were diagnosed with hypercalcemia due to immobilization. Detected levels of calcemia and ionic calcium ranged from 12.2-13.4 mg/dl and 1.44-2.2 mmol/l respectively. None of the children responded to rehydration or frusemide. Treatment was with subcutaneous and/or intranasal calcitonin at a dose of 6-20 IU /kg/day. RESULTS: After calcitonin administration, serum calcium decreased progressively until normal calcemia levels were reached between days 4 and 20 of treatment (8.6-10.5 mg/dl). No treatment-related adverse effects or alterations in phosphorus levels or alkaline phosphatases were observed. CONCLUSION: Calcitonin might be an effective treatment for hypercalcemia due to immobilization in critically ill children.